Evidence map›Paper›PMID 41922881›Full record

SynthesisInternational urology and nephrology2026

Safety and efficacy of adding voclosporin to standard treatment of lupus nephritis in adult patients: a meta-analysis and time-to-event analysis of randomized controlled trials.

Mohamed Saad Sayed, Mohamed R Murad, Hasan Naeem Kareem, Zineddine Belabaci, Marym Taha Abdelhamid, Saadya Hadi Humade, Lava Abdullah, Hebatullah Abdulazeem

Abstract readMeta-AnalysisReview
PubMed Publisher
In one paragraph

Synthesis in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Mohamed Saad SayedFaculty of Medicine, Beni-Suef University, Beni Suef, 62511, Egypt. dr.mohamedsaad11@gmail.com.
Mohamed R MuradFaculty of Medicine, Al-Azahar University, Cairo, Egypt.
Hasan Naeem KareemNursing College, Al-Qadisiyah University, Al-Diwaniya, Iraq.
Zineddine BelabaciFaculty of Medicine, Djillali Liabes University, Sidi Bel Abbes, Algeria.
Marym Taha AbdelhamidTheodor Bilharz Research Institute, Giza, Egypt.
Saadya Hadi HumadeNursing College, Al-Mustaqbal University, Hillah, Babil, 51001, Iraq.
Lava AbdullahPharmacology and toxicology department, Faculty of pharmacy, IUST, Ghabageb, Syrian Arab Republic.
Hebatullah AbdulazeemChair of Epidemiology, TUM School of Medicine and Health, Technical University of Munich, 80809, Munich, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLupus Nephritis (LN) is one of the most common complications of systemic lupus erythematosus. Recent primary studies have stated the superiority of adding voclosporin to standard treatment regimens in reducing proteinuria in LN patients. In this meta-analysis, we evaluate the safety and efficacy of combining voclosporin in patients with LN.

methodsWe searched PubMed, Embase, Scopus, and Web of Science on February 25, 2025, to identify randomized controlled trials (RCTs) that compared the use of voclosporin with standard treatment versus placebo. The Cochrane ROB 2.0 tool was used to assess the quality of the included studies. Cumulative hazard ratio (HR) and risk ratio (RR) with their corresponding 95% confidence intervals (CI) were calculated using R and RevMan software.

results770 patients with LN were included in the three RCTs, with a mean age of 33.01(SD, 9.94) years. Voclosporin significantly achieved a higher reduction of the urine protein-to-creatinine ratio (UPCR) below 50% of its baseline value [HR: 1.97, 95% CI 1.66 to 2.35, log-rank p < 0.001], and below 0.5 g/g [HR: 1.84, 95% CI 1.43 to 2.37, log-rank p < 0.001] compared to placebo. There were higher complete and partial response rates at 6 months and 12 months in the voclosporin group, respectively. The overall adverse events and treatment-related serious adverse events significantly increased in the voclosporin group, which increases the clinical concerns of using voclosporin in LN patients.

conclusionThis analysis highlights the superior efficacy outcomes of voclosporin in inducing LN remission and reducing proteinuria. However, the risk of adverse effects was higher when voclosporin was used. Larger primary studies are needed to explore its exact safety profile.

Indexed as

CyclosporineImmunosuppressive AgentsLupus NephritisAdultDrug Therapy, CombinationHumansProteinuriaRandomized Controlled Trials as TopicTreatment OutcomeCyclosporineImmunosuppressive AgentsvoclosporinCalcineurin inhibitorsLupus nephritisTime-to-event analysisVoclosporin

Identifiers

PMID41922881

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.